What is BioKey?
BioKey operates as a contract development and manufacturing organization (CDMO) with a specialized focus on nutritional and pharmaceutical products. The company offers comprehensive services, encompassing early-phase product development, advanced analytical services, and clinical supply manufacturing. BioKey leverages proprietary oral controlled release technologies to advance the development of both specialty generic and branded products, notably including Maitake Mushroom supplements. Its operations adhere to stringent cGMP certification standards, ensuring the highest quality in production for its clientele in the pharmaceutical and nutraceutical industries.
How much funding has BioKey raised?
BioKey has raised a total of $132K across 1 funding round:
Debt
$132K
Debt (2021): $132K with participation from PPP
What's next for BioKey?
The substantial late-stage funding indicates BioKey is poised for significant scaling and market expansion. This capital infusion is likely to fuel advancements in its proprietary oral controlled release technologies, potentially leading to the launch of new specialty generic and branded products. Furthermore, the investment may support the enhancement of its manufacturing capabilities and the broadening of its service offerings to a wider client base within the pharmaceutical and nutraceutical sectors, solidifying its role as a key CDMO.
See full BioKey company page
